Yousif Capital Management LLC Lowers Position in Pfizer Inc. $PFE

Yousif Capital Management LLC reduced its position in Pfizer Inc. (NYSE:PFE) by 7.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 576,096 shares of the biopharmaceutical company’s stock after selling 43,746 shares during the period. Yousif Capital Management LLC’s holdings in Pfizer were worth $14,702,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. 4WEALTH Advisors Inc. lifted its position in shares of Pfizer by 7.9% in the fourth quarter. 4WEALTH Advisors Inc. now owns 15,866 shares of the biopharmaceutical company’s stock worth $395,000 after buying an additional 1,168 shares in the last quarter. Jefferson Bridge Capital LLC purchased a new stake in shares of Pfizer in the fourth quarter worth about $1,330,000. Perfromance Wealth Partners LLC purchased a new stake in Pfizer during the fourth quarter valued at $237,000. Kentucky Trust Co raised its stake in Pfizer by 2.0% during the fourth quarter. Kentucky Trust Co now owns 63,191 shares of the biopharmaceutical company’s stock valued at $1,573,000 after purchasing an additional 1,240 shares in the last quarter. Finally, Asio Capital LLC purchased a new stake in Pfizer during the fourth quarter valued at $2,859,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on PFE shares. Morgan Stanley set a $27.00 price objective on Pfizer and gave the company a “positive” rating in a research report on Tuesday, March 17th. Bank of America decreased their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. TD Cowen reissued a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Guggenheim increased their target price on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus target price of $28.19.

Pfizer Trading Down 2.6%

Shares of NYSE PFE opened at $27.10 on Wednesday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The business’s 50 day moving average price is $27.14 and its 200-day moving average price is $25.89. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $28.75. The company has a market cap of $154.07 billion, a price-to-earnings ratio of 19.92 and a beta of 0.43.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the prior year, the business posted $0.63 earnings per share. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.